Related references
Note: Only part of the references are listed.The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma
K. Giannopoulos et al.
BRITISH JOURNAL OF CANCER (2012)
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yibin Yang et al.
CANCER CELL (2012)
The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma
Walter M. T. Braga et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Functional modulation of AMP-activated protein kinase by cereblon
Kwang Min Lee et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
Bortezomib-induced BRCAness sensitizes multiple myeloma cells to PARP inhibitors
Paola Neri et al.
BLOOD (2011)
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma
Sumit Madan et al.
BLOOD (2011)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu et al.
BLOOD (2011)
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response
Antonia Lopez-Girona et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients
T. Guglielmelli et al.
EUROPEAN JOURNAL OF CANCER (2011)
Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide
Chad C. Bjorklund et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update
Martha Q. Lacy et al.
LEUKEMIA & LYMPHOMA (2011)
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
H. Quach et al.
LEUKEMIA (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
Christine Galustian et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism
Laure Escoubet-Lozach et al.
CANCER RESEARCH (2009)
Mechanism of action of lenalidomide in hematological malignancies
Venumadhav Kotla et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation
Christina Therapontos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
Michael Wang et al.
BLOOD (2008)
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Antonio Palumbo et al.
BLOOD (2008)
Immunomodulatory drugs Revlimid (R) (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
Dan Zhu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Lei Wu et al.
CLINICAL CANCER RESEARCH (2008)
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
I. Breitkreutz et al.
LEUKEMIA (2008)
IRF4 addiction in multiple myeloma
Arthur L. Shaffer et al.
NATURE (2008)
Dysregulation of large-conductance Ca2+-activated K+ channel expression in nonsyndromal mental retardation due to a cereblon p.R419X mutation
Joseph J. Higgins et al.
NEUROGENETICS (2008)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
Thierry Facon et al.
LANCET (2007)
Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells
Philipp Baumann et al.
EXPERIMENTAL CELL RESEARCH (2007)
Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway
Juergen Knobloch et al.
FASEB JOURNAL (2007)
Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma
Michel Attal et al.
BLOOD (2006)
Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery
Stephane Angers et al.
NATURE (2006)
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
G Anderson et al.
BLOOD (2006)
Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain
S Jo et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma
S Kumar et al.
LEUKEMIA (2004)
Advances in biology of multiple myeloma: clinical applications
T Hideshima et al.
BLOOD (2004)
A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation
JJ Higgins et al.
NEUROLOGY (2004)
Misregulation of gene expression in the redox-sensitive NF-κB-dependent limb outgrowth pathway by thalidomide
JM Hansen et al.
DEVELOPMENTAL DYNAMICS (2002)
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
N Mitsiades et al.
BLOOD (2002)
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
D Gupta et al.
LEUKEMIA (2001)
The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma:: therapeutic applications
T Hideshima et al.
ONCOGENE (2001)
Immunotherapeutic and antitumour potential of thalidomide analogues
JB Marriott et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2001)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
FE Davies et al.
BLOOD (2001)
Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity
JA Keifer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
G Juliusson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Share Paper
